Vanguard Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.5M Hold
2,974,901
– – ﹤0.01% 2786
2026
Q2
$9.07M Buy
2,974,901
+108,552
+4% +$431K ﹤0.01% 2875
2026
Q1
$12.9M Buy
+2,866,349
New +$11.5M ﹤0.01% 2588

Other funds holding LRMR

Vanguard Capital Management's LRMR Position: Q3 2026 in Review

Vanguard Capital Management held its Larimar Therapeutics (LRMR) position steady in Q3 2026 at 2,974,901 shares worth $9.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Vanguard Capital Management first reported a position in LRMR in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.9M in Q1 2026. 146 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Vanguard Capital Management held 2,974,901 shares of Larimar Therapeutics worth $9.5M as of Q3 2026.
  • Vanguard Capital Management left its Larimar Therapeutics share count unchanged in Q3 2026.
  • Larimar Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2786 holding.
  • Vanguard Capital Management first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Larimar Therapeutics position peaked at $12.9M in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.